BioNTech Expands COVID-19 Vaccine Output Again, Forecasts $10bn Revenues
Also Increasing Oncology Trials
Success of the vaccine will fuel the company’s push into immunotherapy, as it reported first commercial sales.
You may also be interested in...
An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.
The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.